Legal & General Group’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Legal & General Group’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$20K	Sell	6,520 -1,204	-16%	-$3.69K	﹤0.01%	2962
2025 Q4	$27.5K	Buy	7,724 +1,148	+17%	+$4.26K	﹤0.01%	2908
2025 Q3	$22.9K	Hold	6,576	–	–	﹤0.01%	2986
2025 Q2	$13.5K	Buy	+6,576	New	+$16.4K	﹤0.01%	3168
2023 Q2	–	Sell	-4,141	Closed	-$2.81K	–	3513
2023 Q1	$2.81K	Hold	4,141	–	–	﹤0.01%	3338
2022 Q4	$6.83K	Hold	4,141	–	–	﹤0.01%	3322
2022 Q3	$19K	Buy	4,141 +534	+15%	+$3.14K	﹤0.01%	3222
2022 Q2	$18K	Buy	+3,607	New	+$26.3K	﹤0.01%	3281

Other funds holding STLN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

KWM

Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return

JAIC

Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return

CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Legal & General Group's STLN Position: Q1 2026 in Review

Legal & General Group reduced its Starling Oncology Institute, Inc. Common Stock (STLN) stake by 16% in Q1 2026, selling an estimated $3.69K and leaving 6,520 shares worth $20K. The position accounts for ﹤0.01% of the portfolio, ranked #2962.

Legal & General Group first reported a position in STLN in Q2 2022 and has held it in 8 quarters since. The position peaked at $27.5K in Q4 2025. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

Legal & General Group held 6,520 shares of Starling Oncology Institute, Inc. Common Stock worth $20K as of Q1 2026.
Legal & General Group sold 1,204 Starling Oncology Institute, Inc. Common Stock shares in Q1 2026, an estimated $3.69K.
Starling Oncology Institute, Inc. Common Stock made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #2962 holding.
Legal & General Group first reported a position in Starling Oncology Institute, Inc. Common Stock in Q2 2022 and has held it in 8 quarters since.
Legal & General Group's Starling Oncology Institute, Inc. Common Stock position peaked at $27.5K in Q4 2025.
115 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.